Massimo Franchini

Summary

Publications

  1. pmc Treatment of hemophilia B: focus on recombinant factor IX
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, Italy
    Biologics 7:33-8. 2013
  2. doi request reprint ABO blood group: old dogma, new perspectives
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, Azienda Ospedaliera Carlo Poma, Mantova, Italy
    Clin Chem Lab Med 51:1545-53. 2013
  3. pmc Issues in pediatric haemophilia care
    Paola Giordano
    Dipartimento di Scienze Biomediche ed Oncologia Umana, Clinica Pediatrica, Università degli Studi di Bari Aldo Moro, Bari, Italy
    Ital J Pediatr 39:24. 2013
  4. ncbi request reprint Alloantibodies in previously untreated hemophilia A patients: the role of environmental factors
    Massimo Franchini
    Transfusion Service, Mantova, Italy
    Hematology 18:183-90. 2013
  5. doi request reprint Acquired FXIII inhibitors: a systematic review
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, Italy
    J Thromb Thrombolysis 36:109-14. 2013
  6. doi request reprint LRP1/CD91 is up-regulated in monocytes from patients with haemophilia A: a single-centre analysis
    M Franchini
    Immunohematology and Transfusion Center, Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy
    Haemophilia 19:e126-32. 2013
  7. ncbi request reprint von Willebrand factor and cancer: a renewed interest
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy
    Thromb Res 131:290-2. 2013
  8. doi request reprint Bleeding complications in patients with hematologic malignancies
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy
    Semin Thromb Hemost 39:94-100. 2013
  9. doi request reprint Helicobacter pylori-associated idiopathic thrombocytopenic purpura: a narrative review
    Massimo Franchini
    Dipartimento di Medicina Trasfusionale ed Ematologia, Azienda Ospedaliera C Poma, Mantova, Italy
    Semin Thromb Hemost 38:463-8. 2012
  10. doi request reprint Acquired inhibitors of coagulation factors: part II
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, C Poma Hospital, Mantova, Italy
    Semin Thromb Hemost 38:447-53. 2012

Collaborators

Detail Information

Publications46

  1. pmc Treatment of hemophilia B: focus on recombinant factor IX
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, Italy
    Biologics 7:33-8. 2013
    ..Further clinical studies are needed to better assess the safety and efficacy (ie, the incidence of adverse reactions and inhibitor development) of newer rFIX products...
  2. doi request reprint ABO blood group: old dogma, new perspectives
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, Azienda Ospedaliera Carlo Poma, Mantova, Italy
    Clin Chem Lab Med 51:1545-53. 2013
    ..In this review, beside its physiologic role in immunohematology and transfusion medicine, we summarize the current knowledge on the association between the ABO blood group and the risk of developing thrombotic events and cancers...
  3. pmc Issues in pediatric haemophilia care
    Paola Giordano
    Dipartimento di Scienze Biomediche ed Oncologia Umana, Clinica Pediatrica, Università degli Studi di Bari Aldo Moro, Bari, Italy
    Ital J Pediatr 39:24. 2013
    ....
  4. ncbi request reprint Alloantibodies in previously untreated hemophilia A patients: the role of environmental factors
    Massimo Franchini
    Transfusion Service, Mantova, Italy
    Hematology 18:183-90. 2013
    ..In this narrative review, we will focus on acquired risk factors, discussing the pathogenic and clinical data available from the literature analysis. ..
  5. doi request reprint Acquired FXIII inhibitors: a systematic review
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, Italy
    J Thromb Thrombolysis 36:109-14. 2013
    ..In this systematic review, we analyse all the published case-reports on anti-FXIII autoantibodies focusing on the clinical features and treatment modalities of this acquired hemorrhagic condition...
  6. doi request reprint LRP1/CD91 is up-regulated in monocytes from patients with haemophilia A: a single-centre analysis
    M Franchini
    Immunohematology and Transfusion Center, Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy
    Haemophilia 19:e126-32. 2013
    ..Further studies are needed to assess the clinical implications of these findings...
  7. ncbi request reprint von Willebrand factor and cancer: a renewed interest
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy
    Thromb Res 131:290-2. 2013
    ..Current knowledge on the link between VWF and cancer is summarized in this review, based on an analysis of the most important experimental and clinical studies...
  8. doi request reprint Bleeding complications in patients with hematologic malignancies
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy
    Semin Thromb Hemost 39:94-100. 2013
    ..In particular, platelet and acquired coagulation abnormalities, bleeding complications in acute leukemia, and hematopoietic stem cell transplantation are discussed...
  9. doi request reprint Helicobacter pylori-associated idiopathic thrombocytopenic purpura: a narrative review
    Massimo Franchini
    Dipartimento di Medicina Trasfusionale ed Ematologia, Azienda Ospedaliera C Poma, Mantova, Italy
    Semin Thromb Hemost 38:463-8. 2012
    ..The current status of the research on the pathogenesis, clinical and therapeutic aspects of H. pylori-associated idiopathic thrombocytopenic purpura in adults and children will be addressed in this narrative review...
  10. doi request reprint Acquired inhibitors of coagulation factors: part II
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, C Poma Hospital, Mantova, Italy
    Semin Thromb Hemost 38:447-53. 2012
    ....
  11. doi request reprint ABO blood group, hypercoagulability, and cardiovascular and cancer risk
    Massimo Franchini
    Dipartimento di Medicina Trasfusionale ed Ematologia, Azienda Ospedaliera Carlo Poma, Mantova, Italy
    Crit Rev Clin Lab Sci 49:137-49. 2012
    ....
  12. doi request reprint Haemophilia B: current pharmacotherapy and future directions
    Massimo Franchini
    Carlo Poma Hospital, Department of Transfusion Medicine and Hematology, Mantova, Italy
    Expert Opin Pharmacother 13:2053-63. 2012
    ....
  13. doi request reprint Immune tolerance induction for patients with severe hemophilia A: a critical literature review
    Massimo Franchini
    Immunohematology and Transfusion Center, C Poma Hospital of Mantova, Mantova, Italy
    J Thromb Thrombolysis 32:439-47. 2011
    ..The currently available literature on ITI in hemophilia A will be critically reviewed in this article. In particular, we will focus on the role of the type of FVIII product on ITI outcome by analyzing the clinical and experimental data...
  14. doi request reprint Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia
    Massimo Franchini
    Department of Pathology and Laboratory Medicine, Immunohematology and Transfusion Center, University Hospital of Parma, Italy
    Semin Thromb Hemost 35:307-12. 2009
    ..Further trials on a large population of patients are needed to establish the role of genetic thrombophilia in the phenotypic expression of severe hemophilia...
  15. ncbi request reprint FEIBA versus NovoSeven in hemophilia patients with inhibitors
    Massimo Franchini
    Department of Hematology and Transfusion Medicine, C Poma Hospital, Mantova, Italy
    Semin Thromb Hemost 39:772-8. 2013
    ..In this review, we summarize the main characteristics of the bypassing agents FEIBA and NovoSeven, briefly discussing available literature data, and in particular, focusing on comparative studies. ..
  16. doi request reprint Extracorporeal immunoadsorption for the treatment of coagulation inhibitors
    Massimo Franchini
    Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy
    Semin Thromb Hemost 35:76-80. 2009
    ..However, further randomized clinical trials are needed to better assess the cost-effectiveness of such procedures...
  17. doi request reprint The use of recombinant activated FVII in postpartum hemorrhage
    Massimo Franchini
    Department of Pathology and Laboratory Medicine, University Hospital of Parma, Immunohematology and Transfusion Center, Parma, Italy
    Clin Obstet Gynecol 53:219-27. 2010
    ..Finally, on the basis of the evidence from the literature and on own experience, we included some recommendations and an algorithm on the therapeutic role of rFVIIa in the management of PPH...
  18. doi request reprint The spectrum of coagulation abnormalities in thyroid disorders
    Pier Paolo Vescovi
    Divisione di Medicina, Ospedale Carlo Poma, Mantova, Italy
    Semin Thromb Hemost 37:7-10. 2011
    ....
  19. ncbi request reprint Inhibitor eradication with rituximab in haemophilia: where do we stand?
    Massimo Franchini
    Department of Transfusion Medicine and Haematology, Carlo Poma Hospital, Mantova, Italy
    Br J Haematol 165:600-8. 2014
    ..This article critically reviews the current knowledge on the use of rituximab in acquired haemophilia or congenital haemophilia complicated by alloantibodies, also providing treatment algorithms for the management of these conditions. ..
  20. doi request reprint Recent improvements in the clinical treatment of coagulation factor inhibitors
    Massimo Franchini
    Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy
    Semin Thromb Hemost 35:806-13. 2009
    ..The most recent options available for treating patients with acquired hemophilia and congenital hemophilia with inhibitors are addressed in this review...
  21. doi request reprint Thrombogenicity and cardiovascular effects of ambient air pollution
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy
    Blood 118:2405-12. 2011
    ....
  22. doi request reprint Anaphylaxis in patients with congenital bleeding disorders and inhibitors
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy
    Blood Coagul Fibrinolysis 20:225-9. 2009
    ..In particular, we focus on the pathophysiology of the inhibitor development and its management...
  23. doi request reprint Atherothrombosis in von Willebrand disease: an analysis of the literature and implications for clinical management
    Massimo Franchini
    Immunohematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy
    Semin Thromb Hemost 38:185-99. 2012
    ....
  24. doi request reprint The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy
    Semin Thromb Hemost 35:644-53. 2009
    ..The main biological and clinical evidence on the relationship between cancer and hemostasis are briefly summarized in this review, as is the potential benefits of anticoagulant therapy in this setting...
  25. doi request reprint Association between venous and arterial thrombosis: clinical implications
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy
    Eur J Intern Med 23:333-7. 2012
    ..The potential clinical implications are also discussed...
  26. doi request reprint Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Laboratory and Pathology Medicine, University Hospital of Parma, Via Gramsci 14, Parma, Italy
    Crit Rev Oncol Hematol 81:82-93. 2012
    ..e., plasma-derived versus recombinant FVIII concentrates) does not seem to influence the inhibitor rate in PUPs with severe hemophilia A...
  27. ncbi request reprint Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy
    Semin Thromb Hemost 39:752-66. 2013
    ..In conclusion, the results of our meta-analysis show that the different types of FVIII products are not associated with different risks of inhibitor development. ..
  28. doi request reprint Factor V Leiden and hemophilia
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy
    Thromb Res 125:119-23. 2010
    ....
  29. doi request reprint New anticoagulants for treatment of venous thromboembolism
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy
    Eur J Intern Med 23:692-5. 2012
    ..g., dabigatran etexilate). The characteristics of these agents and the main results of published clinical studies dealing with VTE treatment are critically summarized in this article...
  30. doi request reprint Thrombin and cancer: from molecular basis to therapeutic implications
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, C Poma Hospital, Mantova, Italy
    Semin Thromb Hemost 38:95-101. 2012
    ..e., hemophilia) and pharmaceutical (i.e., antithrombotic agents) anticoagulation in cancer incidence and survival will be investigated through the analysis of the published experimental and clinical studies...
  31. doi request reprint Multiple gene interaction and modulation of hemostatic balance
    Massimo Franchini
    Department of Pathology and Laboratory Medicine, Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy
    Clin Chem Lab Med 47:1455-60. 2009
    ..The role of genetic factors on the modulation of the phenotypic expression of coagulation disorders will be addressed in this review, with particular emphasis on the underlying pathogenic mechanisms and clinical implications...
  32. doi request reprint Factor V Leiden in women: a thrombotic risk factor or an evolutionary advantage?
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy
    Semin Thromb Hemost 37:275-9. 2011
    ..The results of the most important meta-analyses on the relationship between inherited (factor V Leiden) and acquired thrombophilia in women are analyzed in this review, along with the possible evolutionary role of this mutation...
  33. doi request reprint Pure white cell aplasia induced by mesalazine in a patient with ulcerative colitis
    Francesco Frattini
    Department of Hematology and Transfusion Medicine, Azienda Ospedaliera, Mantova, Italy
    Hematology 18:181-2. 2013
    ..Objectives and importance: Mesalazine is a widely used and generally safe drug for the treatment of chronic inflammatory bowel diseases. Neutropenia rarely complicates this treatment and very few cases have been reported in the literature...
  34. doi request reprint Air pollution and cardiovascular disease
    Massimo Franchini
    Immunohematology and Transfusion Center, Hospital of Mantova, Mantova, Italy
    Thromb Res 129:230-4. 2012
    ..The current knowledge of the short-term and long-term cardiovascular effects of particulate air pollutants is discussed in this review article...
  35. doi request reprint Hyperthyroidism and venous thrombosis: a casual or causal association? A systematic literature review
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy
    Clin Appl Thromb Hemost 17:387-92. 2011
    ....
  36. doi request reprint A new era for anticoagulants
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Italy
    Eur J Intern Med 20:562-8. 2009
    ..The current knowledge on these antithrombotic agents is summarized in this review, particularly focusing on the early results of clinical trials...
  37. ncbi request reprint Hemophilia A in the third millennium
    Massimo Franchini
    Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy
    Blood Rev 27:179-84. 2013
    ..In this narrative review, the actual knowledge on the clinical features and management of patients with hemophilia A is summarized. ..
  38. ncbi request reprint Helicobacter pylori infection and immune thrombocytopenic purpura: an update
    Massimo Franchini
    Transfusion Service, Azienda Ospedaliera di Verona, Italy
    Helicobacter 9:342-6. 2004
    ....
  39. ncbi request reprint Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review
    Massimo Franchini
    Immunohematology and Transfusion Center, City Hospital of Verona, Italy
    Blood Coagul Fibrinolysis 18:589-93. 2007
    ..Large randomized trials are needed, however, to confirm the preliminary results and to assess the safety and dosing regimens of this agent in refractory bleeding associated with disseminated intravascular coagulation...
  40. doi request reprint Disseminated intravascular coagulation in hematologic malignancies
    Massimo Franchini
    Department of Pathology and Laboratory Medicine, Immunohematology and Transfusion Center, University Hospital, Parma, Italy
    Semin Thromb Hemost 36:388-403. 2010
    ..Current approaches and open issues for the management and treatment of these patients are also reviewed...
  41. doi request reprint Von Willebrand disease-associated angiodysplasia: a few answers, still many questions
    Massimo Franchini
    Department of Transfusion Medicine and Haematology, Carlo Poma Hospital, Mantova, Italy
    Br J Haematol 161:177-82. 2013
    ....
  42. pmc Past, present and future of hemophilia: a narrative review
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Milan, Italy
    Orphanet J Rare Dis 7:24. 2012
    ..Finally, intensive research is devoted to gene transfer therapy, the only way to ultimately obtain cure in hemophilia...
  43. doi request reprint Particulate air pollution and cardiovascular risk: short-term and long-term effects
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Italy
    Semin Thromb Hemost 35:665-70. 2009
    ..The literature data on the short-term and long-term cardiovascular effects of particulate air pollutants are discussed in this review from a clinical and mechanistic point of view...
  44. ncbi request reprint Acquired hemophilia A
    Massimo Franchini
    Department of Pathology and Laboratory Medicine, Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy
    Adv Clin Chem 54:71-80. 2011
    ..In this review the actual knowledge on diagnostic and therapeutic aspects of this disease will be summarized...
  45. doi request reprint New antiplatelet agents: why they are needed
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Italy
    Eur J Intern Med 20:733-8. 2009
    ....
  46. doi request reprint The genetic basis of coronary artery disease: from candidate genes to whole genome analysis
    Massimo Franchini
    Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy
    Trends Cardiovasc Med 18:157-62. 2008
    ..At the moment, only distinct but tightly linked single nucleotide polymorphisms on chromosome 9 have been consistently shown to be associated with different clinical phenotypes of coronary artery disease...